KR101817607B1 - 이중 아실화된 ｇｌｐ―１ 유도체 - Google Patents

이중 아실화된 ｇｌｐ―１ 유도체 Download PDF

Info

Publication number
KR101817607B1
KR101817607B1 KR1020127015873A KR20127015873A KR101817607B1 KR 101817607 B1 KR101817607 B1 KR 101817607B1 KR 1020127015873 A KR1020127015873 A KR 1020127015873A KR 20127015873 A KR20127015873 A KR 20127015873A KR 101817607 B1 KR101817607 B1 KR 101817607B1
Authority
KR
South Korea
Prior art keywords
glp
chem
derivative
ethoxy
derivative according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127015873A
Other languages
English (en)
Korean (ko)
Other versions
KR20120103650A (ko
Inventor
패트릭 윌리엄 게리베이
제인 스페츨러
야노스 티보르 코드라
랄스 린데로스
제스퍼 라우
퍼 사우어베르그
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20120103650A publication Critical patent/KR20120103650A/ko
Application granted granted Critical
Publication of KR101817607B1 publication Critical patent/KR101817607B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
KR1020127015873A 2009-12-16 2010-12-16 이중 아실화된 ｇｌｐ―１ 유도체 Expired - Fee Related KR101817607B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09179390.1 2009-12-16
EP09179390 2009-12-16
US28860109P 2009-12-21 2009-12-21
US61/288,601 2009-12-21
PCT/EP2010/069932 WO2011080103A1 (en) 2009-12-16 2010-12-16 Double-acylated glp-1 derivatives

Publications (2)

Publication Number Publication Date
KR20120103650A KR20120103650A (ko) 2012-09-19
KR101817607B1 true KR101817607B1 (ko) 2018-01-11

Family

ID=41800497

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127015873A Expired - Fee Related KR101817607B1 (ko) 2009-12-16 2010-12-16 이중 아실화된 ｇｌｐ―１ 유도체

Country Status (19)

Country Link
US (4) US8815802B2 (enExample)
EP (4) EP2512518A1 (enExample)
JP (5) JP2013514322A (enExample)
KR (1) KR101817607B1 (enExample)
CN (6) CN111560060A (enExample)
AU (1) AU2010338387B2 (enExample)
BR (1) BR112012014475A8 (enExample)
CA (1) CA2784757A1 (enExample)
DK (1) DK2513140T3 (enExample)
ES (2) ES2625735T3 (enExample)
HU (1) HUE027229T2 (enExample)
IL (1) IL219945A (enExample)
MX (1) MX2012006634A (enExample)
PL (1) PL2513140T3 (enExample)
PT (1) PT2513140E (enExample)
RU (1) RU2559540C2 (enExample)
TW (1) TWI484974B (enExample)
WO (3) WO2011080103A1 (enExample)
ZA (1) ZA201204436B (enExample)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
JP6231386B2 (ja) * 2010-11-09 2017-11-15 ノヴォ ノルディスク アー／エス リンカーを有する二重アシル化されたｇｌｐ−１誘導体
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
RU2014103185A (ru) 2011-07-18 2015-08-27 Артс Байолоджикс А/С Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
CN110041399B (zh) 2011-12-29 2023-12-12 诺沃—诺迪斯克有限公司 包含非成蛋白质性的氨基酸的二肽
ES2810153T3 (es) 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
EP2846824B1 (en) 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
DK2866825T3 (da) 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
FR2994848B1 (fr) 2012-08-30 2014-08-22 Univ Paris Curie Traitement de l'arthrose par les hormones incretines ou leurs analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014067084A1 (zh) * 2012-10-31 2014-05-08 深圳翰宇药业股份有限公司 一种艾塞那肽的制备方法
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
MX2015016564A (es) * 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
KR20160029079A (ko) 2013-07-04 2016-03-14 노보 노르디스크 에이/에스 Glp-1 유사 펩티드의 유도체 및 그것의 사용
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
CA2926314C (en) 2013-10-17 2023-08-29 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
AU2014359894B2 (en) 2013-12-06 2020-09-17 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
EP3129041B1 (en) * 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
HUE055931T2 (hu) 2014-06-12 2022-01-28 Ra Pharmaceuticals Inc A komplementaktivitás modulálása
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) * 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
CN107205948B (zh) * 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
WO2017075522A2 (en) * 2015-10-28 2017-05-04 Tufts University Glp-2 polypeptides with improved proteolytic stability, and methods of preparing and using same
AU2016370210A1 (en) 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
GB2551945B (en) * 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN107561168A (zh) * 2016-06-30 2018-01-09 山东新时代药业有限公司 一种聚乙二醇化促胰岛素分泌肽类似物的分析检测方法
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
FR3061715B1 (fr) 2017-01-12 2021-07-30 Institut National Univ Jean Francois Champollion Peptide immunomodulateur
CN110545838A (zh) * 2017-03-08 2019-12-06 因塔西亚制药公司 用于从药物递送装置施用致恶心化合物的设备和方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
RU2753880C1 (ru) * 2017-09-19 2021-08-24 Иммунворк Инк. Фармацевтические конструкции с повышенной аффинностью связывания с альбумином
MA50358A (fr) 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
DK3774862T3 (da) 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
EP3788063B1 (en) 2018-05-04 2023-08-09 Novo Nordisk A/S Gip derivatives and uses thereof
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN109134257A (zh) * 2018-10-08 2019-01-04 扬州工业职业技术学院 一种两步法制备高纯度十二烷基二酸单叔丁酯的方法
CN109111361A (zh) * 2018-10-08 2019-01-01 扬州工业职业技术学院 一种一步法高效制备十二烷基二酸单叔丁酯的方法
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途
WO2020152304A1 (en) 2019-01-24 2020-07-30 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
EP3946261A1 (en) 2019-04-03 2022-02-09 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2021070202A1 (en) * 2019-10-09 2021-04-15 Prasad Alaparthi Lakshmi A method for preparing glp-1 analogue by solid-phase peptide synthesis
KR20220110731A (ko) 2019-11-06 2022-08-09 노보 노르디스크 에이/에스 치매에서의 glp-1 수용체 작용제
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2020388387A1 (en) 2019-11-22 2022-06-02 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
GB202003762D0 (en) * 2020-03-16 2020-04-29 Heptares Therapeutics Ltd GLP receptor agonists
US20230165939A1 (en) 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
KR20230018395A (ko) * 2020-05-29 2023-02-07 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 Glp-1 및 gip 수용체 둘 모두에 대한 이중 작용제 화합물 및 이의 적용
EP4181946A1 (en) * 2020-07-18 2023-05-24 Dr. Reddy's Laboratories Ltd. Improved purification process of semaglutide
PE20231841A1 (es) 2020-07-22 2023-11-21 Novo Nordisk As Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
KR20230083294A (ko) * 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
WO2022096636A1 (en) 2020-11-06 2022-05-12 Novo Nordisk A/S Glp-1 prodrugs and uses hereof
TWI850611B (zh) * 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
WO2022175384A1 (en) * 2021-02-17 2022-08-25 Fundación Universidad Católica De Valencia San Vicente Mártir Small-molecule agents with antiviral activity against rna viruses
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023059846A1 (en) 2021-10-08 2023-04-13 President And Fellows Of Harvard College Ionic liquids for drug delivery
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
CN119173275A (zh) 2022-05-10 2024-12-20 诺和诺德股份有限公司 Glp-1多肽的前药及其用途
IL317902A (en) 2022-06-30 2025-02-01 Sanofi Sa New peptides as selective antagonists of the IL-23 receptor
CN115785249B (zh) * 2022-10-13 2023-07-21 江苏师范大学 一类glp-1类似物及其应用
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
WO2024245946A1 (en) * 2023-05-26 2024-12-05 Gubra A/S Secretin-derived glp1r selective agonists
CN120676965A (zh) * 2023-11-07 2025-09-19 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
WO2007128817A2 (en) * 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU5027299A (en) * 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
US20050059605A1 (en) * 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
EA009366B1 (ru) 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
US20070161087A1 (en) 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
EP1653996A2 (en) * 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
US20070021346A1 (en) * 2005-05-26 2007-01-25 Ewing William R N-terminally modified GLP-1 receptor modulators
EP2289560B1 (en) 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
WO2006096515A2 (en) * 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
KR101011081B1 (ko) 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Ｐｅｇ화된 ｇｌｐ-1 화합물
EP2015776A1 (en) 2006-04-20 2009-01-21 Amgen Inc. Glp-1 compound/glucagon antibody compositions
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
EP2171080A4 (en) * 2007-06-12 2010-10-27 Glaxosmithkline Llc PROCESS FOR DETECTING PROTEIN IN PLASMA
EP2190460B1 (en) * 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
EP2386203B1 (de) 2008-10-15 2013-11-20 Bayer CropScience AG Verwendung von Dithiin-tetracarboximiden zum Bekämpfen phytopathogener Pilze
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
AR077956A1 (es) 2009-09-14 2011-10-05 Bayer Cropscience Ag Combinaciones de compuestos activos
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
WO2007128817A2 (en) * 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative

Also Published As

Publication number Publication date
CN102791731B (zh) 2016-04-20
WO2011073328A1 (en) 2011-06-23
BR112012014475A8 (pt) 2018-07-03
US20110166321A1 (en) 2011-07-07
HUE027229T2 (en) 2016-08-29
EP3000482B1 (en) 2021-04-21
RU2012128547A (ru) 2014-01-27
EP2513140A1 (en) 2012-10-24
CN102655883A (zh) 2012-09-05
JP5411366B2 (ja) 2014-02-12
JP2016094473A (ja) 2016-05-26
CN104327182B (zh) 2020-04-17
WO2011080102A3 (en) 2011-09-09
DK2513140T3 (en) 2016-01-18
CN102686607B (zh) 2014-10-29
US20120329711A1 (en) 2012-12-27
JP6194176B2 (ja) 2017-09-06
WO2011080102A2 (en) 2011-07-07
BR112012014475A2 (pt) 2018-04-24
EP2512518A1 (en) 2012-10-24
WO2011080103A1 (en) 2011-07-07
JP2013514323A (ja) 2013-04-25
JP6006118B2 (ja) 2016-10-12
TWI484974B (zh) 2015-05-21
IL219945A (en) 2016-12-29
CN102686607A (zh) 2012-09-19
JP2013144684A (ja) 2013-07-25
ES2561658T3 (es) 2016-02-29
AU2010338387B2 (en) 2014-10-23
US8648041B2 (en) 2014-02-11
AU2010338387A1 (en) 2012-05-31
CN104311657B (zh) 2020-12-08
JP2013514324A (ja) 2013-04-25
JP2013514322A (ja) 2013-04-25
MX2012006634A (es) 2012-06-21
CA2784757A1 (en) 2011-07-07
US20140179899A1 (en) 2014-06-26
US8815802B2 (en) 2014-08-26
CN102791731A (zh) 2012-11-21
CN111560060A (zh) 2020-08-21
ES2625735T3 (es) 2017-07-20
EP2513140B1 (en) 2015-11-04
US20130053311A1 (en) 2013-02-28
CN104327182A (zh) 2015-02-04
US9556250B2 (en) 2017-01-31
PT2513140E (pt) 2016-03-11
EP2513141A2 (en) 2012-10-24
CN104311657A (zh) 2015-01-28
KR20120103650A (ko) 2012-09-19
RU2559540C2 (ru) 2015-08-10
TW201127396A (en) 2011-08-16
EP3000482A1 (en) 2016-03-30
PL2513140T3 (pl) 2016-04-29
EP2513141B1 (en) 2017-03-01
ZA201204436B (en) 2013-08-28
IL219945A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
KR101817607B1 (ko) 이중 아실화된 ｇｌｐ―１ 유도체
JP6231386B2 (ja) リンカーを有する二重アシル化されたｇｌｐ−１誘導体
US10000542B2 (en) Double-acylated GLP-1 derivatives
PT2696687T (pt) Derivados de glp-1 duplamente acilados
KR20160029079A (ko) Glp-1 유사 펩티드의 유도체 및 그것의 사용
KR20160021183A (ko) Glp-1 유도체 및 그것의 용도
ES2874513T3 (es) Derivados de GLP-1 diacilados

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210106

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210106

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000